Lung cancer trials in Brazil

In Brazil 68 Also abroad 2733

68 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Where
Barretos, Natal, Porto Alegre, Santa Cruz do Sul, São José do Rio Preto, São Paulo
Age
18 years and over
People
780 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00
Phase 3Taking people
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Where
Barretos, Belo Horizonte, Ijuí, Natal, Passo Fundo, Porto Alegre, Recife, Rio de Janeiro, Teresina
Age
18 years and over
People
348 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Where
Barretos, Fortaleza, Itajaí, Porto Alegre, Santa Cruz do Sul, São Paulo
Age
18 years and over
People
530 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00
Phase 3Taking people
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
Where
Barretos, CuritibaPR, Florianópolis, Porto Alegre, Rio de Janeiro, São Paulo
Age
18 years and over
People
420 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07099898
Phase 3Taking people
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Where
Florianópolis, Fortaleza, Porto Alegre, Recife, Ribeirão Preto, Santo André, São Paulo, Vitória
Age
18 years and over
People
675 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00
Phase 3Taking people
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Where
Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
400 worldwide
Run by
AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00
Phase 3Taking people
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
Where
Belo Horizonte, Fortaleza, Porto Alegree, Recife, Santo André, São Paulo, Taubaté, Vitória
Age
18 years and over
People
400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00
Phase 3Taking people
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
Where
Barretos, Porto Alegre, Porto Alegre - RS, São José do Rio Preto
Age
18 years and over
People
670 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07472517 · EU 2025-520565-51-00
Phase 3Taking people
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
Where
Barretos, Florianópolis, Fortaleza, Porto Alegre, Vitória
Age
18 years and over
People
310 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00
Phase 3Taking people
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Where
Barretos, Campinas, Florianópolis, Ijuí, Rio de Janeiro, Salvador, São Paulo, Sorocaba, Vitória
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680790 · EU 2026-526486-21-00
Phase 1/2Taking people
A Study of DS-3939a in Participants With Solid Tumors
Where
Barretos, Natal, Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
400 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07739966 · EU 2026-525218-75-00
Phase 3Taking people
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Where
Barretos, Bauru, Belém, Belo Horizonte, Fortaleza, Itajaí, Natal, Porto Alegre, Rio de Janeiro, São Caetano do Sul, São Paulo, Taubaté, Timbó
Age
18 years and over
People
1,000 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06561386 · EU 2024-513682-40-01
Phase 3Taking people
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Where
Barretos, Bento Gonçalves, Fortaleza, Goiânia, Natal, Passo Fundo, Porto Alegre, Rio de Janeiro, Santa Cruz do Sul
Age
18 years and over
People
680 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06623422 · EU 2023-506327-29-00
Phase 3Taking people
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Where
Pasos Fundo, São Paulo
Age
18 years and over
People
876 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Where
Belo Horizonte, Itajaí, Porto Alegre, São Paulo
Age
18 years and over
People
400 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07541170 · EU 2025-524263-21-01
Phase 3Taking people
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Where
Barretos, Belém, Belo Horizonte, Brasília, Cachoeiro de Itapemirim, Canoas, Itajaí, Natal, Porto Alegre, Recife, Rio de Janeiro, Salvador, Santa Cruz do Sul, Santos, São José do Rio Preto, São Paulo
Age
18 years to 100 years
People
750 worldwide
Run by
Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00
Phase 1/2Taking people
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Where
Barretos, São Paulo
Age
18 years and over
People
320 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05789082 · EU 2023-507171-22-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Barretos, Curitiba, Fortaleza, Natal, Porto Alegre, São Paulo
Age
18 years and over
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06793215
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Where
Blumenau, Passo Fundo, São Paulo
Age
18 years and over
People
680 worldwide
Run by
Pfizer
See details and how to joinNCT07144280 · EU 2025-521281-97-00
Phase 3Taking people
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Where
Barretos, Natal, Porto Alegre, São José do Rio Preto, São Paulo, Teresina
Age
18 years and over
People
850 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361497 · EU 2025-523576-23-00
Phase 3Taking people
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Where
Barretos, Bento Gonçalves, Bequimão, Brasília, Curitiba, Fortaleza, Ijuí, Lago Sul, Londrina, Natal, Porto Alegre, Pouso Alegre, Rio de Janeiro, Salvador, Santo André, São José do Rio Preto, São José dos Campos, São Paulo, Vitória
Age
18 years and over
People
1,264 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06119581 · EU 2023-503412-33-00
Phase 3Taking people
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Bauru, Blumenau, Brasília, Fortaleza, Jaú, Natal, Recife, São José do Rio Preto, São Paulo
Age
18 years and over
People
444 worldwide
Run by
Bayer
See details and how to joinNCT06452277 · EU 2024-511319-91-00
Phase 3Taking people
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Where
Barretos, Belém, Belo Horizonte, Bento Gonçalves, Campinas, Fortaleza, Londrina, Natal, Porto Alegre, Rio de Janeiro, São Paulo
Age
18 years and over
People
700 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06890598 · EU 2024-512302-25-00
Phase 2Taking people
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Where
Barretos, Belo Horizonte, Londrina, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
520 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05498428 · EU 2023-505065-91-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Where
Barretos, Porto Alegre, Rio de Janeiro, Santa Maria, São José do Rio Preto, São Paulo
Age
18 years and over
People
614 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06170788 · EU 2023-503376-24-00